This is a summary of the European public assessment report (EPAR) for Xermelo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Xermelo. For practical information about using Xermelo, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Therapeutic Area (MeSH)
ATC Code
A16A
ATC Item
其它消化道和代谢药物
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| telotristat etiprate | N/A | Telotristat |
EMA Name
Xermelo
Medicine Name
Xermelo
Aliases
N/ANo risk management plan link.
